SKI Market

A+| A| A-|

Indian Indices

Sensex

76,664.21 -999.79
( -1.29%)

Global Indices

Nasdaq

49,330.80 -180.24
(-0.36%)

Dow Jones

7,129.46 -29.44
(-0.41%)

Hang Seng

59,744.07 603.84
(1.02%)

Nikkei 225

10,387.94 -69.07
(-0.66%)

Forex

USD-INR

93.75 0.31
(0.34%)

EUR-INR

109.98 0.10
(0.09%)

GBP-INR

126.66 0.42
(0.33%)

JPY-INR

0.59 0.00
(0.23%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Marksans Pharma Ltd

Industry : Pharmaceuticals - Indian - Formulations

BSE Code

ISIN Demat

Book Value()

524404

INE750C01026

32.9918134

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

MARKSANS

35.49

8748.33

EPS(TTM)

Face Value()

Div & Yield %

5.44

0.41

Back

Generic Engineering Construction & Projects standalone net profit rises 35.16% in the December 2025 quarter

Feb 15,2026

Net profit of Generic Engineering Construction & Projects rose 35.16% to Rs 2.46 crore in the quarter ended December 2025 as against Rs 1.82 crore during the previous quarter ended December 2024. Sales declined 13.61% to Rs 80.59 crore in the quarter ended December 2025 as against Rs 93.29 crore during the previous quarter ended December 2024.

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	80.59	93.29	-14
OPM %	12.35	8.66	-
PBDT	7.73	6.21	24
PBT	4.26	3.02	41
NP	2.46	1.82	35

76,664.21 -999.79 ( -1.29%)

49,330.80 -180.24 (-0.36%)

7,129.46 -29.44 (-0.41%)

59,744.07 603.84 (1.02%)

10,387.94 -69.07 (-0.66%)

93.75 0.31 (0.34%)

109.98 0.10 (0.09%)

126.66 0.42 (0.33%)

0.59 0.00 (0.23%)